Rashidi Turaj, Mahd Azarmdokht Alamdari
Department of Dermatology, Urmia University of Medical Sciences, and Shams Clinicopathology Laboratory, Urmia, Iran.
Int J Dermatol. 2008 Aug;47(8):850-2. doi: 10.1111/j.1365-4632.2008.03700.x.
Alopecia areata is an autoimmune disease with no definitive treatment, and some cases persist despite standard therapies. Sulfasalazine has been reported to show success in the treatment of persistent cases of alopecia areata. Objective To assess the efficacy of sulfasalazine in cases of recalcitrant alopecia areata that do not respond to topical and intralesional corticosteroids, 5% minoxidil, or psoralen plus ultraviolet-A (PUVA) therapy.
Thirty-nine patients with persistent alopecia areata received 3 g of oral sulfasalazine for 6 months, and terminal hair regrowth was quantified as no response, moderate response, or good response.
A good response occurred in 10 of the 39 patients (25.6%), a moderate response in 12 (30.7%), and a poor or no response in 17 (43.5%).
Sulfasalazine can be used as an alternative drug in patients with persistent alopecia areata.
斑秃是一种尚无确切治疗方法的自身免疫性疾病，一些病例即使经过标准治疗仍会持续存在。据报道，柳氮磺胺吡啶在治疗持续性斑秃病例方面取得了成功。目的：评估柳氮磺胺吡啶对顽固性斑秃病例的疗效，这些病例对局部和病灶内注射皮质类固醇、5%米诺地尔或补骨脂素加紫外线A（PUVA）疗法均无反应。
39例持续性斑秃患者口服柳氮磺胺吡啶3克，持续6个月，并将终毛再生情况量化为无反应、中度反应或良好反应。
39例患者中，10例（25.6%）有良好反应，12例（30.7%）有中度反应，17例（43.5%）反应不佳或无反应。
柳氮磺胺吡啶可作为持续性斑秃患者的替代药物。
